Self-assembling nanoparticle engineered from the ferritinophagy complex as a rabies virus vaccine candidate.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
04 Oct 2024
04 Oct 2024
Historique:
received:
17
03
2024
accepted:
24
09
2024
medline:
5
10
2024
pubmed:
5
10
2024
entrez:
4
10
2024
Statut:
epublish
Résumé
Over the past decade, there has been a growing interest in ferritin-based vaccines due to their enhanced antigen immunogenicity and favorable safety profiles, with several vaccine candidates targeting various pathogens advancing to phase I clinical trials. Nevertheless, challenges associated with particle heterogeneity, improper assembly and unanticipated immunogenicity due to the bulky protein adaptor have impeded further advancement. To overcome these challenges, we devise a universal ferritin-adaptor delivery platform based on structural insights derived from the natural ferritinophagy complex of the human ferritin heavy chain (FTH1) and the nuclear receptor coactivator 4 (NCOA4). The engineered ferritinophagy (Fagy)-tag peptide demonstrate significantly enhanced binding affinity to the 24-mer ferritin nanoparticle, enabling efficient antigen presentation. Subsequently, we construct a self-assembling rabies virus (RABV) vaccine candidate by noncovalently conjugating the Fagy-tagged glycoprotein domain III (G
Identifiants
pubmed: 39366932
doi: 10.1038/s41467-024-52908-z
pii: 10.1038/s41467-024-52908-z
doi:
Substances chimiques
Apoferritins
9013-31-4
Rabies Vaccines
0
Ferritins
9007-73-2
FTH1 protein, human
EC 1.-
Antibodies, Viral
0
Antigens, Viral
0
Oxidoreductases
EC 1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8601Informations de copyright
© 2024. The Author(s).
Références
Munro, H. N. & Linder, M. C. Ferritin: structure, biosynthesis, and role in iron metabolism. Physiol. Rev. 58, 317–396 (1978).
pubmed: 347470
doi: 10.1152/physrev.1978.58.2.317
Harrison, P. M. & Arosio, P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta (BBA) Bioenerg. 1275, 161–203 (1996).
doi: 10.1016/0005-2728(96)00022-9
Bhaskar, S. & Lim, S. Engineering protein nanocages as carriers for biomedical applications. NPG Asia Mater. 9, e371 (2017).
pubmed: 32218880
pmcid: 7091667
doi: 10.1038/am.2016.128
Chattopadhyay, S., Chen, J. Y., Chen, H. W. & Hu, C. J. Nanoparticle vaccines adopting virus-like features for enhanced immune potentiation. Nanotheranostics 1, 244–260 (2017).
pubmed: 29071191
pmcid: 5646730
doi: 10.7150/ntno.19796
Gomes, A. C., Mohsen, M. & Bachmann M. F. Harnessing nanoparticles for immunomodulation and vaccines. Vaccines 5, 6 (2017).
Pati, R., Shevtsov, M. & Sonawane, A. Nanoparticle vaccines against infectious diseases. Front. Immunol. 9, 2224 (2018).
pubmed: 30337923
pmcid: 6180194
doi: 10.3389/fimmu.2018.02224
Smith, D. M., Simon, J. K. & Baker, J. R. Jr. Applications of nanotechnology for immunology. Nat. Rev. Immunol. 13, 592–605 (2013).
pubmed: 23883969
pmcid: 7097370
doi: 10.1038/nri3488
Lung, P., Yang, J. & Li, Q. Nanoparticle formulated vaccines: opportunities and challenges. Nanoscale 12, 5746–5763 (2020).
pubmed: 32124894
doi: 10.1039/C9NR08958F
Kanekiyo, M. et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499, 102–106 (2013).
pubmed: 23698367
pmcid: 8312026
doi: 10.1038/nature12202
Kanekiyo, M. et al. Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site. Cell 162, 1090–1100 (2015).
pubmed: 26279189
pmcid: 4757492
doi: 10.1016/j.cell.2015.07.043
Ma, X. et al. Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses. Immunity 53, 1315–1330.e1319 (2020).
pubmed: 33275896
pmcid: 7687490
doi: 10.1016/j.immuni.2020.11.015
He, L. et al. Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates. Sci. Adv. 7, eabf1591 (2021).
Wang, W. et al. Ferritin nanoparticle-based SpyTag/SpyCatcher-enabled click vaccine for tumor immunotherapy. Nanomedicine 16, 69–78 (2019).
pubmed: 30529790
doi: 10.1016/j.nano.2018.11.009
He, L. et al. Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles. Nat. Commun. 7, 12041 (2016).
pubmed: 27349934
pmcid: 4931238
doi: 10.1038/ncomms12041
Houser, K. V. et al. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nat. Med. 28, 383–391 (2022).
pubmed: 35115706
pmcid: 10588819
doi: 10.1038/s41591-021-01660-8
Tai, W. et al. Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant. Signal Transduct. Target. Ther. 7, 173 (2022).
pubmed: 35650183
pmcid: 9157036
doi: 10.1038/s41392-022-01041-8
Saunders, K. O. et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature 594, 553–559 (2021).
pubmed: 33971664
pmcid: 8528238
doi: 10.1038/s41586-021-03594-0
Caldeira, J. C. & Peabody, D. S. Thermal stability of RNA phage virus-like particles displaying foreign peptides. J. Nanobiotechnol. 9, 22 (2011).
doi: 10.1186/1477-3155-9-22
Janssens, M. E. et al. Folding properties of the hepatitis B core as a carrier protein for vaccination research. Amino Acids 38, 1617–1626 (2010).
pubmed: 19957000
doi: 10.1007/s00726-009-0365-1
Rodrigues, M. Q., Alves, P. M. & Roldão, A. Functionalizing ferritin nanoparticles for vaccine development. Pharmaceutics 13, 1621 (2021).
Nguyen, B. & Tolia, N. H. Protein-based antigen presentation platforms for nanoparticle vaccines. NPJ Vaccines 6, 70 (2021).
pubmed: 33986287
pmcid: 8119681
doi: 10.1038/s41541-021-00330-7
Zhang, Y. N. et al. Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants. Sci. Adv. 7, eabj3107 (2021).
pubmed: 34669468
pmcid: 8528426
doi: 10.1126/sciadv.abj3107
Kang, Y. F. et al. Rapid development of SARS-CoV-2 spike protein receptor-binding domain self-assembled nanoparticle vaccine candidates. ACS Nano 15, 2738–2752 (2021).
pubmed: 33464829
doi: 10.1021/acsnano.0c08379
Daniels, T. R., Delgado, T., Rodriguez, J. A., Helguera, G. & Penichet, M. L. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 121, 144–158 (2006).
pubmed: 16904380
doi: 10.1016/j.clim.2006.06.010
Kleven, M. D., Jue, S. & Enns, C. A. Transferrin receptors TfR1 and TfR2 bind transferrin through differing mechanisms. Biochemistry 57, 1552–1559 (2018).
pubmed: 29388418
doi: 10.1021/acs.biochem.8b00006
Kawabata, H. Transferrin and transferrin receptors update. Free Radic. Biol. Med. 133, 46–54 (2019).
pubmed: 29969719
doi: 10.1016/j.freeradbiomed.2018.06.037
Cheng, Y., Zak, O., Aisen, P., Harrison, S. C. & Walz, T. Structure of the human transferrin receptor-transferrin complex. Cell 116, 565–576 (2004).
pubmed: 14980223
doi: 10.1016/S0092-8674(04)00130-8
Montemiglio, L. C. et al. Cryo-EM structure of the human ferritin-transferrin receptor 1 complex. Nat. Commun. 10, 1121 (2019).
pubmed: 30850661
pmcid: 6408514
doi: 10.1038/s41467-019-09098-w
Chasteen, N. D. & Harrison, P. M. Mineralization in ferritin: an efficient means of iron storage. J. Struct. Biol. 126, 182–194 (1999).
pubmed: 10441528
doi: 10.1006/jsbi.1999.4118
Asano, T. et al. Distinct mechanisms of ferritin delivery to lysosomes in iron-depleted and iron-replete cells. Mol. Cell. Biol. 31, 2040–2052 (2011).
pubmed: 21444722
pmcid: 3133360
doi: 10.1128/MCB.01437-10
Mancias, J. D., Wang, X., Gygi, S. P., Harper, J. W. & Kimmelman, A. C. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature 509, 105–109 (2014).
pubmed: 24695223
pmcid: 4180099
doi: 10.1038/nature13148
Mancias, J. D. et al. Ferritinophagy via NCOA4 is required for erythropoiesis and is regulated by iron dependent HERC2-mediated proteolysis. Elife 4, e10308 (2015).
Gryzik, M. et al. Expression and characterization of the ferritin binding domain of nuclear receptor coactivator-4 (NCOA4). Biochim. Biophys. Acta Gen. Subj. 1861, 2710–2716 (2017).
pubmed: 28754384
doi: 10.1016/j.bbagen.2017.07.015
Amarasinghe, G. K. et al. Taxonomy of the order Mononegavirales: update 2018. Arch. Virol. 163, 2283–2294 (2018).
pubmed: 29637429
pmcid: 6076851
doi: 10.1007/s00705-018-3814-x
Fooks, A. R. et al. Renewed public health threat from emerging lyssaviruses. Viruses 13, 1769 (2021).
Ugolini, G. & Hemachudha, T. Rabies: changing prophylaxis and new insights in pathophysiology. Curr. Opin. Infect. Dis. 31, 93–101 (2018).
pubmed: 29293476
doi: 10.1097/QCO.0000000000000420
Sriwijitalai, W. & Wiwanitkit, V. Rabies, rabies vaccine, and renal failure: clinical issues. Saudi J. Kidney Dis. Transplant. 30, 560–563 (2019).
doi: 10.4103/1319-2442.261327
Hemachudha, T. et al. Human rabies: neuropathogenesis, diagnosis, and management. Lancet Neurol. 12, 498–513 (2013).
pubmed: 23602163
doi: 10.1016/S1474-4422(13)70038-3
Parize, P. et al. Systematic booster after rabies pre-exposure prophylaxis to alleviate rabies antibody monitoring in individuals at risk of occupational exposure. Vaccines 9, 309 (2021).
Bordenave, G. Louis Pasteur (1822-1895). Microbes Infect. 5, 553–560 (2003).
pubmed: 12758285
doi: 10.1016/S1286-4579(03)00075-3
Kissling, R. E. Growth of rabies virus in non-nervous tissue culture. Proc. Soc. Exp. Biol. Med. 98, 223–225 (1958).
pubmed: 13554599
doi: 10.3181/00379727-98-23997
Kondo, A. Growth characteristics of rabies virus in primary chick embryo cells. Virology 27, 199–204 (1965).
pubmed: 5840891
doi: 10.1016/0042-6822(65)90160-1
Wiktor, T. J. et al. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc. Natl. Acad. Sci. USA 81, 7194–7198 (1984).
pubmed: 6095272
pmcid: 392104
doi: 10.1073/pnas.81.22.7194
Zhang, Y. et al. A novel rabies vaccine based-on toll-like receptor 3 (TLR3) agonist PIKA adjuvant exhibiting excellent safety and efficacy in animal studies. Virology 489, 165–172 (2016).
pubmed: 26765968
doi: 10.1016/j.virol.2015.10.029
Wijaya, L. et al. An accelerated rabies vaccine schedule based on toll-like receptor 3 (TLR3) agonist PIKA adjuvant augments rabies virus specific antibody and T cell response in healthy adult volunteers. Vaccine 35, 1175–1183 (2017).
pubmed: 28118938
doi: 10.1016/j.vaccine.2016.12.031
Liang, M. et al. A single dose of recombinant VSV-RABV(G) vaccine provides full protection against RABV challenge. Virol. Sin. 37, 455–458 (2022).
pubmed: 35618603
pmcid: 9243626
doi: 10.1016/j.virs.2022.02.008
Faber, M. et al. Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus. Proc. Natl. Acad. Sci. USA 106, 11300–11305 (2009).
pubmed: 19581599
pmcid: 2706273
doi: 10.1073/pnas.0905640106
Kaur, M., Saxena, A., Rai, A. & Bhatnagar, R. Rabies DNA vaccine encoding lysosome-targeted glycoprotein supplemented with Emulsigen-D confers complete protection in preexposure and postexposure studies in BALB/c mice. FASEB J. 24, 173–183 (2010).
pubmed: 19741168
doi: 10.1096/fj.09-138644
Garg, R., Kaur, M., Saxena, A., Prasad, R. & Bhatnagar, R. Alum adjuvanted rabies DNA vaccine confers 80% protection against lethal 50 LD(50) rabies challenge virus standard strain. Mol. Immunol. 85, 166–173 (2017).
pubmed: 28267643
doi: 10.1016/j.molimm.2017.02.011
Hellgren, F. et al. Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses. Nat. Commun. 14, 3713 (2023).
pubmed: 37349310
pmcid: 10287699
doi: 10.1038/s41467-023-39421-5
Yang, D. K. et al. Oral immunization of mice with recombinant rabies vaccine strain (ERAG3G) induces complete protection. Clin. Exp. Vaccine Res. 4, 107–113 (2015).
pubmed: 25648184
pmcid: 4313102
doi: 10.7774/cevr.2015.4.1.107
World Health Organization. Food, Agriculture Organization of the United Nations, World Organisation for Animal Health. Zero By 30: The Global Strategic Plan to End Human Deaths from Dog-mediated Rabies by 2030 (World Health Organization, 2018).
Roche, S., Rey, F. A., Gaudin, Y. & Bressanelli, S. Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G. Science 315, 843–848 (2007).
pubmed: 17289996
doi: 10.1126/science.1135710
Baquero, E. et al. Structure of the low pH conformation of Chandipura virus G reveals important features in the evolution of the vesiculovirus glycoprotein. PLoS Pathog. 11, e1004756 (2015).
pubmed: 25803715
pmcid: 4372607
doi: 10.1371/journal.ppat.1004756
Kadlec, J., Loureiro, S., Abrescia, N. G. A., Stuart, D. I. & Jones, I. M. The postfusion structure of baculovirus gp64 supports a unified view of viral fusion machines. Nat. Struct. Mol. Biol. 15, 1024–1030 (2008).
pubmed: 18776902
doi: 10.1038/nsmb.1484
Vollmer, B. et al. The prefusion structure of herpes simplex virus glycoprotein B. Sci. Adv. 6, eabc1726 (2020).
de Melo, G. D., Hellert, J., Gupta, R., Corti, D. & Bourhy, H. Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy. Curr. Opin. Virol. 53, 101204 (2022).
pubmed: 35151116
doi: 10.1016/j.coviro.2022.101204
Hellert, J. et al. Structure of the prefusion-locking broadly neutralizing antibody RVC20 bound to the rabies virus glycoprotein. Nat. Commun. 11, 596 (2020).
pubmed: 32001700
pmcid: 6992781
doi: 10.1038/s41467-020-14398-7
Yang, F. et al. Structural analysis of rabies virus glycoprotein reveals pH-dependent conformational changes and interactions with a neutralizing antibody. Cell Host Microbe 27, 441–453.e447 (2020).
pubmed: 32004500
doi: 10.1016/j.chom.2019.12.012
Albertini, A. A., Baquero, E., Ferlin, A. & Gaudin, Y. Molecular and cellular aspects of rhabdovirus entry. Viruses 4, 117–139 (2012).
pubmed: 22355455
pmcid: 3280520
doi: 10.3390/v4010117
World Health Organization. WHO Expert Consultation on Rabies: Second Report (World Health Organization, 2013).
Lazear, H. M. et al. Interferon-λ restricts West Nile virus neuroinvasion by tightening the blood-brain barrier. Sci. Transl. Med. 7, 284ra259 (2015).
doi: 10.1126/scitranslmed.aaa4304
Donnelly, R. P. & Kotenko, S. V. Interferon-lambda: a new addition to an old family. J. Interferon Cytokine Res. 30, 555–564 (2010).
pubmed: 20712453
pmcid: 2925029
doi: 10.1089/jir.2010.0078
Rosenberg, E. S. et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278, 1447–1450 (1997).
pubmed: 9367954
doi: 10.1126/science.278.5342.1447
Zhu, J., Yamane, H. & Paul, W. E. Differentiation of effector CD4 T cell populations*. Annu. Rev. Immunol. 28, 445–489 (2010).
pubmed: 20192806
pmcid: 3502616
doi: 10.1146/annurev-immunol-030409-101212
Ertl, H. C. J. New rabies vaccines for use in humans. Vaccines 7, 54 (2019).
Hoelzgen, F. et al. Structural basis for the intracellular regulation of ferritin degradation. Nat. Commun. 15, 3802 (2024).
pubmed: 38714719
pmcid: 11076521
doi: 10.1038/s41467-024-48151-1
Zakeri, B. et al. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc. Natl. Acad. Sci. USA 109, E690–E697 (2012).
pubmed: 22366317
pmcid: 3311370
doi: 10.1073/pnas.1115485109
Graham, B. S. Rapid COVID-19 vaccine development. Science 368, 945–946 (2020).
pubmed: 32385100
doi: 10.1126/science.abb8923
Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. eLife 7, e42166 (2018).
pubmed: 30412051
pmcid: 6250425
doi: 10.7554/eLife.42166
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
pubmed: 28165473
doi: 10.1038/nmeth.4169
Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331–332 (2017).
pubmed: 28250466
pmcid: 5494038
doi: 10.1038/nmeth.4193
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010).
pubmed: 20383002
pmcid: 2852313
doi: 10.1107/S0907444910007493
Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221 (2010).
pubmed: 20124702
pmcid: 2815670
doi: 10.1107/S0907444909052925
Otwinowski, Z. & Minor, W. [20] Processing of X-ray diffraction data collected in oscillation mode. in Methods in Enzymology (Academic Press, 1997).
Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12–21 (2010).
pubmed: 20057044
doi: 10.1107/S0907444909042073
World Organisation for Animal Health (WOAH). WOAH terrestrial manual 2023. In Manual of Diagnostic Tests and Vaccines for Terrestrial Animals (ed Health) (World Organisation for Animal Health, 2023).
Li, J. et al. An mRNA-based rabies vaccine induces strong protective immune responses in mice and dogs. Virol. J. 19, 184 (2022).
pubmed: 36371169
pmcid: 9652961
doi: 10.1186/s12985-022-01919-7
Tu, Z. et al. Inhibition of rabies virus by 1,2,3,4,6-penta-O-galloyl-β-d-Glucose involves mTOR-dependent autophagy. Viruses 10, 201 (2018).